REGN Q3 September 2022 earnings are on 11/3 at 6:30am. Regeneron Pharmaceuticals (REGN) reported Q2 June 2022 earnings of $9.77 per share on revenue of $2.9 billion. The consensus earnings estimate was $8.53 per share on revenue of $2.8 billion. Revenue fell 44.4% compared to the same quarter a year ago. REGN short entry based on its $754 all time high major resistance level which it didn't even break through during the global covid pandemic in 2020. Plus, the nearest support going into earnings on 11/3 is the SMA50 around $663. Any short term pop up is an opportunity to get a higher strike put with a further dated expiry imo.
Q3 September 2022 Consensus: EPS = $8.77 Revenue = $2.82 B
Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends...
7 Common mistakes: +5% portfolio trades, capital risk management Beware of analyst's motives Emotions & Opinions FOMO : bad timing, the market is ruthless, be shrewd Lack of planning & discipline Forgetting restraint Obdurate repetitive errors, no adaptation
7 Important tools: Trading View app!, Brokerage UI Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big, organized desk Reading books, playing chess Sorted watch-list
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.